• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

浅表性膀胱癌的辅助免疫治疗

Adjuvant immunotherapy in superficial bladder cancer.

作者信息

Morales A

出版信息

Natl Cancer Inst Monogr. 1978 Dec(49):315-9.

PMID:748787
Abstract

The use of BCG as an intracavitary form of immunotherapy in human bladder cancers is discussed. The result of a clinical trial in which BCG is administered in the treatment of human bladder cancers is reported. Possible uses of this tumor model in the study of immunotherapy employing BCG are suggested.

摘要

本文讨论了卡介苗作为人类膀胱癌腔内免疫疗法的应用。报告了一项使用卡介苗治疗人类膀胱癌的临床试验结果。还提出了该肿瘤模型在卡介苗免疫治疗研究中的可能用途。

相似文献

1
Adjuvant immunotherapy in superficial bladder cancer.浅表性膀胱癌的辅助免疫治疗
Natl Cancer Inst Monogr. 1978 Dec(49):315-9.
2
Intravesical bacillus Calmette-Guérin therapy for T1 superficial bladder cancer.卡介苗膀胱内灌注治疗T1期浅表性膀胱癌
Urol Int. 2008;80(1):74-9. doi: 10.1159/000111734. Epub 2008 Jan 18.
3
Intravesical bacillus Calmette-Guerin therapy for stage T1 grade 3 transitional cell carcinoma of the bladder: recurrence, progression and survival in a study of 57 patients.膀胱内卡介苗治疗T1期3级膀胱移行细胞癌：57例患者的复发、进展及生存情况研究
J Urol. 2003 Jun;169(6):2110-2. doi: 10.1097/01.ju.0000066840.42991.4a.
4
Maintenance bacillus Calmette-Guerin immunotherapy for recurrent TA, T1 and carcinoma in situ transitional cell carcinoma of the bladder: a randomized Southwest Oncology Group Study.卡介苗维持免疫疗法用于复发性TA、T1期及原位膀胱移行细胞癌：西南肿瘤协作组的一项随机研究
J Urol. 2000 Apr;163(4):1124-9.
5
[Radical cystectomy for superficial tumors in the BCG era].[卡介苗（BCG）时代针对浅表肿瘤的根治性膀胱切除术]
Arch Esp Urol. 2002 Jan-Feb;55(1):50-6.
6
T2a transitional cell carcinoma of the bladder: long-term experience with intravesical immunoprophylaxis with bacillus Calmette-Guerin.膀胱T2a期移行细胞癌：卡介苗膀胱内免疫预防的长期经验
J Urol. 2003 Mar;169(3):931-4; discussion 934-5. doi: 10.1097/01.ju.0000049002.75782.39.
7
[Intravesical adjuvant chemotherapy for superficial bladder cancer -- results of a survey in Saxony].[浅表性膀胱癌的膀胱内辅助化疗——萨克森州的一项调查结果]
Aktuelle Urol. 2005 Aug;36(4):337-41. doi: 10.1055/s-2004-830188.
8
Recurrence and progression of stage T1, grade 3 transitional cell carcinoma of the bladder following intravesical immunotherapy with bacillus Calmette-Guerin.卡介苗膀胱内免疫治疗后T1期3级膀胱移行细胞癌的复发与进展
J Urol. 2000 Jun;163(6):1697-701.
9
Immunoprophylactic intravesical application of bacillus Calmette-Guerin after transurethral resection of superficial bladder cancer.经尿道切除浅表性膀胱癌后卡介苗的免疫预防性膀胱内应用。
Croat Med J. 2003 Apr;44(2):187-92.
10
[Adjuvant local BCG-immunotherapy in patients with urothel cancer of the bladder (author's transl)].
Wien Med Wochenschr. 1981 Oct 31;131(20):501-6.

引用本文的文献

1
Nano-Bacillus Calmette-Guérin immunotherapies for improved bladder cancer treatment.纳米卡介苗免疫疗法改善膀胱癌治疗。
J Zhejiang Univ Sci B. 2024 Jul 11;25(7):557-567. doi: 10.1631/jzus.B2300392.
2
Repurposing Infectious Diseases Vaccines Against Cancer.将传染病疫苗用于癌症防治。
Front Oncol. 2021 May 13;11:688755. doi: 10.3389/fonc.2021.688755. eCollection 2021.
3
Pleural Effusion Caused by Bacillus Calmette-Guérin Immunotherapy for Bladder Cancer.卡介苗免疫疗法治疗膀胱癌所致胸腔积液
Open Forum Infect Dis. 2017 Jun 17;4(3):ofx126. doi: 10.1093/ofid/ofx126. eCollection 2017 Summer.
4
Combined therapeutic effects of an immunomodulator, PSK, and chemotherapy with carboquone on rat bladder carcinoma.免疫调节剂PSK与卡波醌联合化疗对大鼠膀胱癌的治疗效果
Cancer Chemother Pharmacol. 1985;15(1):54-8. doi: 10.1007/BF00257295.
5
Adjuvant Bestatin immunotherapy in patients with transitional cell carcinoma of the bladder. Clinical results of a randomized trial.膀胱移行细胞癌患者的辅助性贝司他汀免疫疗法。一项随机试验的临床结果。
Cancer Immunol Immunother. 1987;25(1):41-6. doi: 10.1007/BF00199299.
6
Therapy of bladder cancer.
Int Urol Nephrol. 1987;19(4):399-413. doi: 10.1007/BF02550357.